About the Facility and Team

Developed by a team of McGill University Health Centre researchers, DOvEEgene is the new genomic uterine pap test. Whereas the conventional pap test screens for cervical cancer by finding abnormal cells under a microscope, the DOvEEgene test is developed to screen for both ovarian and endometrial cancers.

The cutting-edge DOvEEgene test is the only test capable of making the distinction between cancer and non-cancer cells in pre- and post-menpausal women. The full test process includes completing a questionnaire, collecting a saliva sample, a blood sample, a transvaginal ultrasound, a conventional pap-test and the DOvEEgene test.

The research team was working at the Royal Victoria Hospital in Montreal, and were using UV technology to disinfect their ultrasound probes. As they started looking into expanding operations to an additional location, they began the procurement process for another device for ultrasound probe high level disinfection (HLD). One of the DOvEEgene researchers had recently attended a conference and spoke with the Nanosonics team about trophon technology. After requesting a trophon2 demonstration, their team was impressed by the prompt response, expertise and professionalism from Nanosonics.